SDK Provides LED for Research on Rice-Based Oral Vaccine "MucoRice"
2018年4月24日 - 04:00PM
JCN Newswire (英)
Showa Denko (SDK; TSE:4004) has entered into a contract with
Astellas Pharma Inc. (Astellas) to take charge of a portion of the
role Astellas is expected to fulfill under the provisions of the
collaborative research agreement aiming at the practical
application of the rice-based oral vaccine "MucoRice-CTB"
(MucoRice) signed by Astellas, the Institute of Medical Science,
the University of Tokyo, Chiba University, and ASAHI KOGYOSHA CO.,
LTD. Under this contract, SDK will start to conduct its business in
this April and provide Astellas with LED lighting equipment and
other devices for plant growth.
SDK will contribute its share to the development of MucoRice by
utilizing know-how nourished through years of experience in plant
factories.
About Showa Denko
Showa Denko's LED lighting equipment for plant growth contains the
Company's proprietary LED chips that emit deep-red light with the
wavelengths of 660 nm (optimum light for plant's photosynthesis) at
the world's highest level of efficiency* and LED chips that emit
blue light. On the basis of S-method (SHIGYOTM Method) which
irradiates deep-red and blue lights alternately in optimized
cycles, and makes a lettuce grow to 150 grams in weight in 30 days
after seeding, SDK's original system for plant factories controls
lighting environment as desired, and supports various plant growth
technologies. For more information, please visit
www.sdk.co.jp/english/.
Note: *As of April 24, 2018
For further information, contact:
Public Relations Office
Phone: 81-3-5470-3235
Source: Showa Denko K.K.
Copyright 2018 JCN Newswire . All rights reserved.